Finally, the use of TAK-242 and other compounds interfering with the TLR-4 signalling pathway emerge as a potential therapeutic adjuvant strategy for the treatment of some neuropsychiatric diseases, such as depression or chronic fatigue syndrome, characterized by mild neuroinflammation and oxidative/nitrosative damage. The gene discussed is TLR4; the disease is major depressive disorder.